UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5213-5218

2009

Volltextzugriff (PDF)

Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type

Advances in Hematology, 2010, Vol.2010 (2010), p.211-215

2010

Volltextzugriff (PDF)

Flow Cytometric Detection of the Classical Hodgkin Lymphoma: Clinical and Research Applications

Advances in Hematology, 2011, Vol.2011 (2011), p.97-105

2011

Volltextzugriff (PDF)

Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy

Blood, 2019-11, Vol.134 (Supplement_1), p.63-63

2019

Volltextzugriff (PDF)

Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma

Blood, 2020-11, Vol.136 (Supplement 1), p.33-34

2020

Volltextzugriff (PDF)

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Blood, 2017-12, Vol.130, p.5163-5163

2017

Volltextzugriff (PDF)

Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients

Blood, 2018-11, Vol.132 (Supplement 1), p.1600-1600

2018

Volltextzugriff (PDF)

Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq

Blood, 2019-11, Vol.134 (Supplement_1), p.5217-5217

2019

Volltextzugriff (PDF)

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL

Blood, 2019-11, Vol.134 (Supplement_1), p.2815-2815

2019

Volltextzugriff (PDF)

Prognostic value of baseline SUV max in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7540-7540

2019

Volltextzugriff (PDF)

Peripheral T-Cell Lymphoma: Review and Updates of Current Management Strategies

Advances in Hematology, 2010, Vol.2010 (2010), p.202-209

2010

Volltextzugriff (PDF)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

Advances in Hematology, 2011, Vol.2011 (2011), p.260-266

2011

Volltextzugriff (PDF)

Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib

Blood, 2018-11, Vol.132 (Supplement 1), p.4151-4151

2018

Volltextzugriff (PDF)

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood, 2019-11, Vol.134 (Supplement_1), p.3987-3987

2019

Volltextzugriff (PDF)

Treatment of dendritic cell sarcoma: 18-year experience at the MD Anderson Cancer Center

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8596-8596

2014

Volltextzugriff (PDF)

Lenalidome in combination with rituximab for relapsed or refractory mantel cell lymphoma: Updated analysis of a phase 2 trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8542-8542

2015

Volltextzugriff (PDF)

Ten-year follow-up of pentostatin combined with cyclophosphamide, and rituximab in previously untreated indolent B-cell lymphoma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e19040-e19040

2017

Volltextzugriff (PDF)

The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP

Clinical lymphoma, myeloma and leukemia, 2013-02, Vol.13 (1), p.15-18

2013

Volltextzugriff (PDF)

10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8528-8528

2014

Volltextzugriff (PDF)

Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8564-8564

2014

Volltextzugriff (PDF)

Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8538-8538

2015

Volltextzugriff (PDF)

Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)

Blood, 2013-11, Vol.122 (21), p.3028-3028

2013

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Kollektion

EZB Electronic Journals Library
(39)
Publisher or Other Site
(34)
Journals@Ovid Full Text
(10)
MEDLINE
(3)
IngentaConnect
(2)
Elsevier ScienceDirect Journals Complete
(2)
IngentaConnect Journals
(1)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type

Flow Cytometric Detection of the Classical Hodgkin Lymphoma: Clinical and Research Applications

Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy

Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients

Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL

Prognostic value of baseline SUV max in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy

Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Peripheral T-Cell Lymphoma: Review and Updates of Current Management Strategies

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib

Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Treatment of dendritic cell sarcoma: 18-year experience at the MD Anderson Cancer Center

Lenalidome in combination with rituximab for relapsed or refractory mantel cell lymphoma: Updated analysis of a phase 2 trial

Ten-year follow-up of pentostatin combined with cyclophosphamide, and rituximab in previously untreated indolent B-cell lymphoma

The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP

10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study

Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience

Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL)

Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)

Suchergebnisse filtern